Core Insights - Theravance Biopharma has launched a disease education campaign titled "Power in the Periphery" aimed at enhancing the understanding of neurogenic orthostatic hypotension (nOH) related to Multiple System Atrophy (MSA) [1][2] - The campaign was introduced at the International Congress of Parkinson's Disease and Movement Disorders, emphasizing the company's commitment to educating healthcare professionals about the complexities of nOH [2] Company Overview - Theravance Biopharma focuses on transforming the treatment landscape for specialty respiratory and neurologic diseases through innovative medicine development [6] Disease Context - Multiple System Atrophy (MSA) is a progressive brain disorder affecting movement and balance, with approximately 50,000 patients in the US, where 70-90% experience nOH symptoms [4] - Neurogenic orthostatic hypotension (nOH) is characterized by a significant drop in blood pressure upon standing, leading to debilitating symptoms such as dizziness and fainting [5]